Session » Abstracts: Vasculitis – ANCA-Associated (1764–1769)
- 10:00AM-10:15AM
-
Abstract Number: 1764
Development and Validation of a Simulation Model for Induction of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
- 10:15AM-10:30AM
-
Abstract Number: 1765
Maintenance of remission with rituximab versus azathioprine in newly diagnosed or relapsing eosinophilic granulomatosis with polyangiitis. A prospective, randomized, controlled, double-blind trial
- 10:30AM-10:45AM
-
Abstract Number: 1766
Clinical Impact of Incomplete B-cell Depletion in ANCA-Associated Vasculitis Patients Receiving Maintenance Rituximab Therapy: a Retrospective Study
- 10:45AM-11:00AM
-
Abstract Number: 1767
Identification of C3 complement fragments in lesional tissues in ANCA-associated vasculitis
- 11:00AM-11:15AM
-
Abstract Number: 1768
TREM-1 and TREM-2 Define Inflammatory and Protective Axes in ANCA-Associated Glomerulonephritis
- 11:15AM-11:30AM
-
Abstract Number: 1769
Classification of Relapses of Eosinophilic Granulomatosis with Polyangiitis After Two-Years of Treatment with Anti-Interleukin-5/Receptor Therapy